These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
48. Opioid and cannabinoid modulation of precipitated withdrawal in delta(9)-tetrahydrocannabinol and morphine-dependent mice. Lichtman AH; Sheikh SM; Loh HH; Martin BR J Pharmacol Exp Ther; 2001 Sep; 298(3):1007-14. PubMed ID: 11504797 [TBL] [Abstract][Full Text] [Related]
49. Discriminative stimulus effects of the cannabinoid antagonist, SR 141716A, in delta -sup-9-tetrahydrocannabinol-treated rhesus monkeys. McMahon LR; France CP Exp Clin Psychopharmacol; 2003 Nov; 11(4):286-93. PubMed ID: 14599262 [TBL] [Abstract][Full Text] [Related]
50. Effects of SR 141716A after acute or chronic cannabinoid administration in dogs. Lichtman AH; Wiley JL; LaVecchia KL; Neviaser ST; Arthur DB; Wilson DM; Martin BR Eur J Pharmacol; 1998 Sep; 357(2-3):139-48. PubMed ID: 9797029 [TBL] [Abstract][Full Text] [Related]
51. Decrease in prostaglandin level is a prerequisite for the expression of cannabinoid withdrawal: a quasi abstinence approach. Anggadiredja K; Yamaguchi T; Tanaka H; Shoyama Y; Watanabe S; Yamamoto T Brain Res; 2005 Dec; 1066(1-2):201-5. PubMed ID: 16336946 [TBL] [Abstract][Full Text] [Related]